Edition:
United Kingdom

Allogene Therapeutics Inc (ALLO.OQ)

ALLO.OQ on NASDAQ Stock Exchange Global Select Market

26.27USD
16 Aug 2019
Change (% chg)

$-0.04 (-0.15%)
Prev Close
$26.31
Open
$26.50
Day's High
$26.76
Day's Low
$26.06
Volume
190,134
Avg. Vol
162,674
52-wk High
$35.55
52-wk Low
$21.67

Latest Key Developments (Source: Significant Developments)

Allogene Therapeutics Reports Second Quarter 2019 Financial Results
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Allogene Therapeutics Inc ::ALLOGENE THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.41.Q2 EARNINGS PER SHARE ESTIMATE $-0.46 -- REFINITIV IBES DATA.SEES FULL-YEAR 2019 NET LOSSES TO BE BETWEEN $200 MILLION AND $210 MILLION.ALLOGENE THERAPEUTICS - AS OF JUNE 30, ALLOGENE HAD $650.2 MILLION IN CASH, CASH EQUIVALENTS, AND INVESTMENTS, VERSUS $721.4 MILLION AS OF DECEMBER 31, 2018.  Full Article

Allogene Therapeutics Reports Q4, FY2018 Results
Friday, 8 Mar 2019 

March 8 (Reuters) - Allogene Therapeutics Inc ::ALLOGENE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.37.Q4 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.PHASE 1 ALLO-501 CLINICAL TRIAL ON-TRACK FOR INITIATION IN 1H 2019.EXPECTS FULL YEAR 2019 NET LOSSES TO BE BETWEEN $200 MILLION AND $210 MILLION.AS OF DECEMBER 31, 2018, ALLOGENE HAD $721.4 MILLION IN CASH, CASH EQUIVALENTS, AND INVESTMENTS.ON TRACK TO FILE AN IND APPLICATION IN 2019 FOR ALLO-715.  Full Article

Allogene Therapeutics in collaboration with Servier, announces FDA clearance of the Ind For Allo-501, an anti-Cd19 Allogeneic Car T (Allocar T) therapy
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Allogene Therapeutics Inc ::ALLOGENE THERAPEUTICS, IN COLLABORATION WITH SERVIER, ANNOUNCES FDA CLEARANCE OF THE IND FOR ALLO-501, AN ANTI-CD19 ALLOGENEIC CAR T (ALLOCAR T) THERAPY.ALLOGENE THERAPEUTICS - ALPHA PHASE 1 TRIAL TO TREAT UP TO 24 PATIENTS & IS ON TRACK FOR INITIATION IN H1 2019.ALLOGENE THERAPEUTICS - TO INITIATE ALPHA STUDY FOR ALLO-501 IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA.ALLOGENE THERAPEUTICS - ALLO-647, ALLOGENE'S PROPRIETARY ANTI-CD52 ANTIBODY, TO BE ADMINISTERED AS PART OF LYMPHODEPLETION REGIMEN.  Full Article

BUZZ-U.S. STOCKS ON THE MOVE-Eventbrite, oil stocks, Big Lots, Exxon Mobil, Costco

* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks were on pace for their fifth day of losses on Friday, after weak U.S. jobs data in February added to concerns over cooling global growth that was sparked by a sharp fall in China's exports and a prolonged slowdown in the eurozone. At 1:55 p.m. ET, the Dow Jones Industrial Average was down 0.56 perc